Fluoroquinolone Resistance in Bacteroides fragilis following Sparfloxacin Exposure

ABSTRACT In vitro pharmacodynamic studies investigating the antimicrobial properties of five fluoroquinolones, (trovafloxacin, sparfloxacin, clinafloxacin, levofloxacin, and ciprofloxacin) againstBacteroides fragilis ATCC 23745 were conducted. The times required to reduce the viable counts by 3 log units were as follows: clinafloxacin, 2.9 h; levofloxacin, 4.6 h; trovafloxacin, 6 h; and sparfloxacin, 10 h. Exposure to ciprofloxacin did not achieve a 3-log decrease in viable counts. The susceptibility ofB. fragilis was determined both prior to exposure and following 24 h of exposure to each of the five fluoroquinolones tested. The MICs of clinafloxacin, levofloxacin, trovafloxacin, sparfloxacin, ciprofloxacin, metronidazole, cefoxitin, chloramphenicol, and clindamycin were determined by the broth microdilution method. The MICs for B. fragilis preexposure were as follows: clinafloxacin, 0.25 μg/ml; trovafloxacin, 0.5 μg/ml; sparfloxacin, 2 μg/ml; levofloxacin, 2 μg/ml; and ciprofloxacin, 8 μg/ml. Similar pre- and postexposure MICs were obtained for cultures exposed to trovafloxacin, clinafloxacin, levofloxacin, and ciprofloxacin. However, following 24 h of exposure to sparfloxacin, a fluoroquinolone-resistant strain emerged. The MICs for this strain were as follows: clinafloxacin, 1 μg/ml; trovafloxacin, 4 μg/ml; sparfloxacin, 16 μg/ml; levofloxacin, 16 μg/ml; and ciprofloxacin, 32 μg/ml. No changes in the susceptibility of B. fragilispre- and postexposure to sparfloxacin were noted for metronidazole (MIC, 1 μg/ml), cefoxitin (MIC, 4 μg/ml), chloramphenicol (MIC, 4 μg/ml), and clindamycin (MIC, 0.06 μg/ml). Resistance remained stable as the organism was passaged on antibiotic-free agar for 10 consecutive days. Mutant B. fragilis strains with decreased susceptibility to clinafloxacin, trovafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin were selected on brucella blood agar containing 8× the MIC of levofloxacin at a frequencies of 6.4 × 10−9, 4× the MICs of trovafloxacin and sparfloxacin at frequencies of 2.2 × 10−9 and 3.3 × 10−10, respectively, and 2× the MIC of clinafloxacin at a frequency of 5.5 × 10−11; no mutants were selected with ciprofloxacin. The susceptibilities of strains to trovafloxacin, levofloxacin, clinafloxacin, sparfloxacin, and ciprofloxacin before and after exposure to sparfloxacin were modestly affected by the presence of reserpine (20 μg/ml), an inhibitor of antibiotic efflux. The mechanism of fluoroquinolone resistance is being explored, but it is unlikely to be efflux due to a lack of cross-resistance to unrelated antimicrobial agents and to the fact that the MICs for strains before and after exposure to sparfloxacin are minimally affected by reserpine.

[1]  F. Yoshimura,et al.  Active Efflux of Norfloxacin byBacteroides fragilis , 1998, Antimicrobial Agents and Chemotherapy.

[2]  Jerome J. Schentag,et al.  Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy , 1998, Antimicrobial Agents and Chemotherapy.

[3]  D. Citron,et al.  Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections , 1997, Antimicrobial agents and chemotherapy.

[4]  K. Bowker,et al.  Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. , 1997, The Journal of antimicrobial chemotherapy.

[5]  M. Jacobs,et al.  Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes. , 1997, The Journal of antimicrobial chemotherapy.

[6]  R. Hill,et al.  Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium. , 1997, The Journal of antimicrobial chemotherapy.

[7]  E. Goldstein Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  L. B. Hovde,et al.  Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model , 1996, Antimicrobial agents and chemotherapy.

[9]  H. Neu,et al.  In vitro activity of the new fluoroquinolone CP-99,219 , 1994, Antimicrobial Agents and Chemotherapy.

[10]  M. Jacobs,et al.  Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes , 1994, Antimicrobial Agents and Chemotherapy.

[11]  K. Aldridge Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria , 1994, Antimicrobial Agents and Chemotherapy.

[12]  E. Perea,et al.  Comparative activities of eight quinolones against members of the Bacteroides fragilis group , 1994, Antimicrobial Agents and Chemotherapy.

[13]  J. Rotschafer,et al.  Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system , 1993, Antimicrobial Agents and Chemotherapy.

[14]  E. Goldstein Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Rotschafer,et al.  Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads , 1993, Antimicrobial Agents and Chemotherapy.

[16]  R. Nichols,et al.  Wound and intraabdominal infections: microbiological considerations and approaches to treatment. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  S. Schuldiner,et al.  Mutants of the Bacillus subtilis multidrug transporter Bmr with altered sensitivity to the antihypertensive alkaloid reserpine. , 1993, The Journal of biological chemistry.

[18]  E. Goldstein,et al.  Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria , 1992, Antimicrobial Agents and Chemotherapy.

[19]  A. Neyfakh,et al.  The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein , 1992, Antimicrobial Agents and Chemotherapy.

[20]  V. Bidnenko,et al.  Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Hooper,et al.  Mechanisms of action of and resistance to ciprofloxacin. , 1987, The American journal of medicine.

[22]  M. Gellert,et al.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[23]  I. Herrera Theory of connectivity for formally symmetric operators. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Bush,et al.  Antimicrobial resistance in anaerobes. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  F. Goldstein,et al.  Trends in bacterial resistance to fluoroquinolones. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D. Citron,et al.  Wadsworth Anaerobic Bacteriology Manual , 1980 .